# Sai Life Sciences (SAILIFE) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/sailife

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹1,768
- Change: +10.88%
- As of: 2026-11-06
- 1D return: +10.88%
- 5D return: +13.52%
- 1M return: +17.43%
- Latest complete quarter: fy27_q2

## Faxioms Analysis

_As of 2026-11-06_

### Technical Outlook

As of 2026-11-06, SAILIFE exhibits a strong bullish technical structure across daily, weekly, and monthly timeframes. The stock closed at ₹1768.00, up +10.9% on the day, trading near its available high with a range position of +95.5% over the past year. Trend indicators confirm this strength: the ADX is 26.14 on the daily chart (established trend) and 74.6 on the monthly chart (strong trend), while price remains above all key moving averages and the Supertrend indicator.

Participation was extreme on 2026-11-06, with volume surging 27.49 times the average alongside a +12.5% intraday range. This follows a downward gap on 2026-11-04, which appears to have been absorbed as buyers stepped in aggressively. Risk metrics show an annualized volatility of +38.6% and a maximum historical drawdown of -18.6%. Current support levels are identified at ₹1663.20 (-5.93%) and ₹1631.10 (-7.74%).

The setup is confirmed by sustained price action above short-term averages. A weakening of this setup would be signaled by a close below the 20-day moving average or a break below the ₹1663.20 support level, which could invalidate the immediate bullish momentum.

- Trend Strength: Bullish across all horizons; Daily ADX 26.14 (established), Monthly ADX 74.6 (strong).
- Momentum & Participation: Closed at ₹1768.00 (+10.9%); Extreme volume anomaly on 2026-11-06 with 27.49x volume ratio.
- Price Positioning: Trading near yearly highs (+95.5% in 252-day range); Price above all supplied MAs and Supertrend.
- Key Levels: Immediate support at ₹1663.20 (-5.93%) and ₹1631.10 (-7.74%); Resistance at current highs.

- Harami
- Hammer
- Morning Star
- Inside Bar
- Outside Bar
- Doji

### What Changed

Sai Life Sciences reported unaudited financial results for the half-year ended September 30, 2026, on November 5, 2026. The company recorded a Profit Before Tax of ₹4,561.73 million for the first half and ₹1,283.08 million for the second quarter. Concurrently, the Board appointed three senior management personnel effective November 5, 2026: Mr. Sidhartha Das (Senior Vice President & Head - Human Resources), Mr. Vijay Kumar Suthari (Vice President - Head Quality & Regulatory Affairs), and Mr. Sriram Gopalakrishnan (Senior Vice President - Corporate Communications). The company also allotted 108,005 fully paid-up equity shares under ESOP 2008 and MESOP 2018, increasing its issued share capital from ₹21,24,72,716 to ₹21,25,80,721. Deloitte Haskins & Sells LLP issued unmodified limited-review conclusions on these results. On November 6, 2026, the company uploaded audio recordings of the earnings call to its website and informed the NSE and BSE of the publication. The stock price was observed at ₹1,768.00 on November 6, 2026, compared to a previous close of ₹1,599.00.

- H1 FY2026 Profit Before Tax reached ₹4,561.73 million, with Q2 standalone PBT at ₹1,283.08 million.
- Board appointed three new senior executives effective November 5, 2026, covering HR, Quality/Regulatory, and Corporate Communications.
- Issued share capital increased by 108,005 shares to ₹21,25,80,721 following ESOP exercises.
- Stock price rose to ₹1,768.00 on November 6, 2026, from ₹1,599.00 previously.

- [Sai Life Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20261106_150545723.xml)
- [Sai Life Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026150610_Stx_Audio_Recording_06112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026152718_Stx_Newspaper_UFR_06112026_S.pdf)
- [Sai Life Sciences Limited has informed the Exchange about change in Management |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225952_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225725_Stx_Outcome_of_BM_05112026_Signed.pdf)

### Official Filings

Sai Life Sciences Limited reported unaudited financial results for the half-year ended September 30, 2026, on November 5, 2026. The company recorded a Profit Before Tax of ₹4,561.73 million for the first half and ₹1,283.08 million for the second quarter. Deloitte Haskins & Sells LLP issued unmodified limited-review conclusions on these results. Concurrently, the Board appointed three senior management personnel effective November 5, 2026: Sidhartha Das (Head - Human Resources), Vijay Kumar Suthari (Head Quality & Regulatory Affairs), and Sriram Gopalakrishnan (Corporate Communications). Additionally, the company allotted 108,005 fully paid-up equity shares upon the exercise of options under ESOP 2008 and MESOP 2018, increasing its issued share capital from ₹21,24,72,716 to ₹21,25,80,721. An earnings conference call was held on November 6, 2026, with recordings made available to investors.

- Profit Before Tax stood at ₹1,283.08 million for Q2 and ₹4,561.73 million for H1 ended September 30, 2026.
- Three senior management appointments were approved effective November 5, 2026, covering HR, Quality/Regulatory, and Corporate Communications.
- Issued share capital increased by 108,005 shares to ₹21,25,80,721 following ESOP exercises under ESOP 2008 and MESOP 2018.

- [Sai Life Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20261106_150545723.xml)
- [Sai Life Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026150610_Stx_Audio_Recording_06112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026152718_Stx_Newspaper_UFR_06112026_S.pdf)
- [Sai Life Sciences Limited has informed the Exchange about change in Management |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225952_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225725_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange regarding Allotment of 108005 Shares. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026230549_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_24081_WebXMLFile_20261105_231206142.xml)
- [Sai Life Sciences has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20261105_231443081.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754390_05112026112122_WEB.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754391_05112026112228_WEB.xml)

### Fundamentals

Sai Life Sciences demonstrates a robust expansion in profitability and cash generation, though it faces near-term margin pressure from rising costs. For the full year ended March 2026, sales grew 4% year-on-year to ₹2,192 crore, while net profit surged 105% to ₹349 crore. This earnings acceleration is supported by strong operating leverage, with operating profit rising to ₹634 crore and ROCE improving significantly to 20%. Cash flow quality remains high, with CFO/EBITDA at 86% and total cash from operations increasing to ₹509 crore.

However, recent quarterly trends indicate tightening margins. In Q2 FY2026-27 (ended September 2026), revenue rose sequentially to ₹659 crore, but expenses increased faster, reaching ₹531 crore. Finance costs also ticked up to ₹10.9 crore. Despite this, net profit remained resilient at ₹98.3 crore, yielding an EPS of ₹4.63. The balance sheet shows active capital deployment, with Fixed Assets growing to ₹1,815 crore and CWIP rising sharply to ₹270 crore as of March 2026. Borrowings have been reduced steadily from ₹928 crore in March 2024 to ₹288 crore in March 2026, indicating deleveraging alongside expansion.

The most critical checkpoint for the next period is whether the company can stabilize expense growth relative to revenue, particularly given the sequential rise in finance costs and other expenses in Q2 FY2026-27.

- Profitability Surge: Full-year March 2026 net profit jumped 105% to ₹349 crore on 4% sales growth, driven by improved operating margins and a ROCE increase to 20%.
- Cash Flow Strength: Operating cash flow reached ₹509 crore in March 2026, with CFO/EBITDA conversion holding at a healthy 86%, reflecting strong earnings quality.
- Margin Pressure in Latest Quarter: Q2 FY2026-27 saw expenses rise sequentially to ₹531 crore against ₹659 crore revenue, pressuring margins despite net profit remaining stable at ₹98.3 crore.
- Balance Sheet Deleveraging: Total borrowings fell consistently from ₹928 crore (Mar 2024) to ₹288 crore (Mar 2026), even as Fixed Assets expanded to ₹1,815 crore.

### Bull Case

Sai Life Sciences demonstrates strong technical momentum across multiple timeframes as of 6 November 2026, with the stock trading at ₹1768.00 and a market capitalization of approximately ₹33,866 crore. The daily Supertrend indicator remains bullish, supported by a Plus DI of 45.7 against a Minus DI of 11.08, indicating dominant buying pressure. This strength is corroborated by the monthly timeframe, where the ADX stands at 74.6, signaling a robust trend. Over the past year, the stock has delivered a return of +91.7%, contributing to a year-to-date gain of +96.4% and an all-time high return of +133.2% since the start of the tracked period. While the stock faces resistance near its recent high of ₹1814.90, support levels are identified at ₹1663.20 (5.93% below) and ₹1631.10 (7.74% below). The broader Indian pharmaceutical sector also shows resilience, with the sectoral index rising 27% year-to-date in 2026, driven by domestic demand and margin improvements.

- Multi-timeframe technical strength: Daily and monthly Supertrends are bullish, with monthly ADX at 74.6 indicating a strong underlying trend.
- Significant price appreciation: The stock has gained +91.7% over the last year and +96.4% year-to-date, closing at ₹1768.00 on 6 November 2026.
- Defined support structure: Key support levels exist at ₹1663.20 and ₹1631.10, providing reference points for potential pullbacks.
- Sector tailwinds: The Indian pharma sector index rose 27% year-to-date in 2026, reflecting resilient domestic demand and improving margins.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Sai Life Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20261106_150545723.xml)
- [Sai Life Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026150610_Stx_Audio_Recording_06112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026152718_Stx_Newspaper_UFR_06112026_S.pdf)
- [Sai Life Sciences Limited has informed the Exchange about change in Management |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225952_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225725_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange regarding Allotment of 108005 Shares. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026230549_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_24081_WebXMLFile_20261105_231206142.xml)
- [Sai Life Sciences has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20261105_231443081.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754390_05112026112122_WEB.xml)

### FAQs

**What financial results did Sai Life Sciences report for the half-year ended September 30, 2026?**

The Board approved unaudited standalone and consolidated results showing a Profit Before Tax of ₹1,283.08 million for Q2 and ₹4,561.73 million for H1. Deloitte Haskins & Sells LLP issued unmodified limited-review conclusions on these figures.

**How has the stock performed over the past year compared to its recent monthly trends?**

Sai Life Sciences delivered a +91.7% return over the past year and a +96.4% year-to-date return as of November 6, 2026. Recent momentum includes a +13.5% one-month return and a +26.7% ten-day return, with the daily Supertrend indicating a bullish trend.

**What management changes and capital adjustments occurred in early November 2026?**

On November 5, 2026, the company appointed three senior personnel: Mr. Sidhartha Das (HR), Mr. Vijay Kumar Suthari (Quality & Regulatory), and Mr. Sriram Gopalakrishnan (Corporate Communications). The Board also allotted 108,005 equity shares under ESOPs, increasing paid-up share capital from ₹21,24,72,716 to ₹21,25,80,721.

**Where are the key technical support levels for the stock following its recent rally?**

With the closing price at ₹1,768.00 on November 6, 2026, immediate support is identified at ₹1,663.20 (-5.93%), followed by ₹1,631.10 (-7.74%) and ₹1,612.80 (-8.78%). A pivot support level exists at ₹1,580.70 (-10.59%). The stock experienced a maximum drawdown of -18.6% historically.

- [Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- [Sai Life Sciences Limited has informed the Exchange about Audio Recording/Video Recording |SUBJECT: Analyst/Investor Meet Para A-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20261106_150545723.xml)
- [Sai Life Sciences Limited has informed the Exchange about Link of Recording |SUBJECT: Analysts/Institutional Investor Meet/Con. Call Updates](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026150610_Stx_Audio_Recording_06112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026152718_Stx_Newspaper_UFR_06112026_S.pdf)
- [Sai Life Sciences Limited has informed the Exchange about change in Management |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225952_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. |SUBJECT: Outcome of Board Meeting](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225725_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange regarding Allotment of 108005 Shares. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026230549_Stx_Outcome_of_BM_05112026_Signed.pdf)
- [Sai Life Sciences Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_24081_WebXMLFile_20261105_231206142.xml)
- [Sai Life Sciences has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20261105_231443081.xml)
- [Integrated Filing- Financials|Original|](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754390_05112026112122_WEB.xml)
## Technical analytics

- As of: 2026-11-06
- Daily trend: Weak Uptrend
- Weekly trend: Moderate Uptrend
- Pivot point: ₹1,580.7
- Risk regime: Price Risk Requires Attention

### Support levels
- 1453.2
- 1414.65
- 1360.6

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +10.88% |
| return_10 | +26.71% |
| return_1m | +13.47% |
| return_1y | +91.69% |
| return_20 | +17.43% |
| return_3m | +25.08% |
| return_5 | +13.52% |
| return_6m | +63.83% |
| return_since_start | +133.25% |
| return_ytd | +96.39% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -18.55% |
| annualized_volatility | +38.57% |

## Quarterly financials

- Latest complete quarter: fy27_q2

# Sai Life Sciences Limited Q2 FY2026-27: Revenue up 23% year on year

Revenue from operations rose 22.5% year on year to ₹658.6 crore in the quarter ended 30 September 2026, while profit before tax increased 17.2% to ₹131.3 crore. Sequentially, revenue grew 18.8% and profit before tax rose 34.0%, with expenses increasing more slowly than revenue; investing cash outflow was ₹553 crore and free cash flow was negative ₹363 crore.

## Revenue growth and expenses

Revenue from operations reached ₹658.6 crore, up from ₹554.3 crore in Q1 FY2026-27 and ₹537.5 crore in Q2 FY2025-26. It was the highest quarterly revenue in the supplied series, ahead of ₹602.1 crore in Q4 FY2025-26.

Total expenses rose 15.5% sequentially to ₹531.3 crore, below the 18.8% increase in revenue. Employee benefit expense was ₹198.1 crore and materials consumed cost ₹170.1 crore. Other expenses increased 22.1% to ₹99.5 crore from ₹81.5 crore in Q1, while finance costs rose 43.3% to ₹10.9 crore from ₹7.6 crore. Depreciation and amortisation expense was ₹48.1 crore.

## Profit and earnings per share

Profit before tax was ₹131.3 crore, up 34.0% from ₹98.0 crore in Q1 FY2026-27 and 17.2% from ₹112.1 crore in Q2 FY2025-26. Profit for the period from continuing operations increased 34.2% sequentially to ₹98.3 crore, compared with ₹73.3 crore in Q1 and ₹83.8 crore a year earlier. Tax expense was ₹33.0 crore, versus ₹24.7 crore in Q1.

Basic EPS was ₹4.63, up from ₹3.46 in Q1 FY2026-27 and ₹4.01 in Q2 FY2025-26. Trailing twelve-month EPS was ₹17.79.

## Cash flow and investment

Operating cash flow was ₹190.1 crore in the quarter. Investing activities used ₹553.1 crore, resulting in reported free cash flow of negative ₹363.0 crore; financing activities provided ₹312.1 crore.

Cash and cash equivalents stood at ₹30.9 crore on 30 September 2026, down from ₹81.9 crore on 31 March 2026 and ₹207.7 crore on 30 September 2025. Capital work in progress increased to ₹559.6 crore from ₹270.5 crore at 31 March 2026, while property, plant and equipment rose to ₹2,027.6 crore from ₹1,808.7 crore. Equity stood at ₹2,688.1 crore at quarter-end, compared with ₹2,483.7 crore at 31 March 2026.

## Key Takeaway

Revenue reached a new high in the supplied quarterly series, with year-on-year growth translating into higher profit despite rising costs. The strong sequential earnings improvement came alongside negative free cash flow, a lower cash balance and a larger asset base, keeping investment and cash generation central to assessing the quarter’s progress.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +34.53%
- FII holding: +19.65%
- DII holding: +32.71%
- Mutual fund holding: +29.47%
- Retail holding: +5.10%
- Promoter pledged: +0.00%

### Major reported shareholders

- MYTREYI KANUMURI Partner of Marigold Partners (Partnership Firm) — +10.45% (Partnership Firms)
- INVESCO INDIA MANUFACTURING FUND — +7.44%
- RANGA RAJU KANUMURI Partner of Sunflower Partners (Partnership Firm) — +7.35% (Partnership Firms)
- NIPPON LIFE INDIA TRUSTEE LTD A/C NIPPON INDIA MNC — +6.66%
- GOKARAJU SUBBA RAJU — +4.54%
- MYTREYI KANUMURI Partner of Tulip Partners (Partnership Firm) — +4.37% (Partnership Firms)
- RANGA RAJU KANUMURI Partner of Lily Partners (Partnership Firm) — +3.25% (Partnership Firms)
- AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL F — +2.90%
- ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C — +2.76%
- SMALLCAP WORLD FUND, INC — +2.57%

## Official filings

- 2026-11-06 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20261106_150545723.xml)
- 2026-11-06 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026150610_Stx_Audio_Recording_06112026_Signed.pdf)
- 2026-11-06 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026152718_Stx_Newspaper_UFR_06112026_S.pdf)
- 2026-11-05 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225952_Stx_Outcome_of_BM_05112026_Signed.pdf)
- 2026-11-05 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026225725_Stx_Outcome_of_BM_05112026_Signed.pdf)
- 2026-11-05 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_05112026230549_Stx_Outcome_of_BM_05112026_Signed.pdf)
- 2026-11-05 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_24081_WebXMLFile_20261105_231206142.xml)
- 2026-11-05 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20261105_231443081.xml)
- 2026-11-05 — Financial Results Filing: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754390_05112026112122_WEB.xml)
- 2026-11-05 — Financial Results Filing: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1754391_05112026112228_WEB.xml)
- 2026-11-05 — Earnings Presentation: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026001507_Stx_Investor_Presentation_05112026_Signed.pdf)
- 2026-11-05 — Press Release: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_06112026001244_Stx_Press_Release_05112026_Signed.pdf)
- 2026-10-19 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_24081_WebXMLFile_20261019_165955375.xml)
- 2026-10-19 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_19102026170520_Stx_Intimation_Investor_Analyst_Signed.pdf)
- 2026-10-12 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_12102026192546_Stx_Intimation_ESOP_Allotment_Signed.pdf)
- 2026-10-12 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20261012_192440621.xml)
- 2026-10-05 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_05102026105343_Stx_Intimation_DP_Reg_74_5__Signed.pdf)
- 2026-10-01 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_24081_WebXMLFile_20261001_110806353.xml)
- 2026-10-01 — Board Meeting Notice: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_24081_WebXMLFile_20261001_110806353.xml)
- 2026-10-01 — Board Meeting Notice: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_01102026110753_Stx_Prior_Intimation_BM_05112026_Signed.pdf)
- 2026-09-28 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_24081_WebXMLFile_20260928_112330612.xml)
- 2026-09-28 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_28092026112739_Stx_Intimation_TWC_Signed.pdf)
- 2026-09-18 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_24081_WebXMLFile_20260918_181226322.xml)
- 2026-09-18 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_18092026181531_Stx_Intimation_ESOP_Allotment_Signed.pdf)
- 2026-09-17 — Generic Announcement: Sai Life Sciences Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SAILIFE_17092026125920_Stx_Intimation_Outcome_Proceedings_Signed.pdf)

## News and market events

- 2026-11-06 — Economic Times: **Sai Life Sciences shares rally 9% after Q2 results; net profit rises 17%, revenue up 23%** — Sai Life Sciences shares rose nearly 9% to a fresh 52-week high after the company reported strong Q2FY27 results, with net profit increasing 17% year-on-year and revenue from operations growing 23%. The pharmaceutical research and manufacturing firm attributed this performance to sustained business momentum and expanding strategic relationships with global pharmaceutical companies. These financial gains occurred alongside significant capital expenditure of Rs 621 crore in the first half of FY27. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/sai-life-sciences-shares-rally-9-after-q2-results-net-profit-rises-17-revenue-up-23/articleshow/135595958.cms)
- 2026-11-05 — Economic Times: **Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return** — India's pharmaceutical sector has emerged as the best-performing equity segment in 2026, with the sectoral index rising 27% year-to-date and leading stocks like Laurus Labs delivering returns of up to 112%. This outperformance is attributed to resilient domestic demand, improving US business margins, and new product opportunities such as semaglutide, which have supported an underlying earnings recovery. While analysts view the rally as sustainable due to predictable earnings, some caution that valuations may limit further market-beating gains compared to other sectors. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/pills-are-paying-off-pharma-stocks-lead-2026-rally-with-up-to-112-return/articleshow/135561757.cms)
- 2026-10-23 — Mint: **Already jumped 55% in 2026, PL Capital sees more returns in Sai Lifesciences shares | Check target, upside** — PL Capital believes the company is well positioned to benefit from increasing pharmaceutical outsourcing, a deep commercial pipeline and capacity expansion — [Source](https://www.livemint.com/market/stock-market-news/already-jumped-55-in-2026-pl-capital-sees-more-returns-in-sai-lifesciences-shares-check-target-upside-11792742770583.html)
- 2026-10-21 — MONEYCONTROL: **Buy Sai Life Sciences; target of Rs 1620: Prabhudas Lilladher** — Prabhudas Lilladher, Sai Life Sciences, buy, Recommendations — [Source](https://www.moneycontrol.com/news/business/stocks/buy-sai-life-sciences-target-of-rs-1620-prabhudas-lilladher-14056567.html)
- 2026-09-30 — CNBC-TV18: **This multibagger pharma stock is down 10% from record high—CFO reveals growth plan** — Sivaramakrishnan Chittor, CFO, Sai Life Sciences, said the company continues to see steady progress in the China Plus One opportunity as large pharmaceutical companies diversify their supply chains. — [Source](https://www.cnbctv18.com/market/stocks/sai-life-sciences-down-10-from-record-high-cfo-reveals-growth-plan-20001690.htm)
- 2026-09-28 — CNBC-TV18: **Sensex closes over 1,000 points lower: 5 reasons behind today's market fall** — All four frontline indices closed nearly 2% lower, with the Nifty Bank emerging as the biggest underperformer. Rising crude continued to weigh on the market, with seven Nifty stocks closing at their 52-week lows. — [Source](https://www.cnbctv18.com/market/sensex-closes-over-1000-points-lower-5-reasons-behind-todays-market-fall-20000056.htm)
- 2026-09-10 — CNBC-TV18: **IRB Infra, Ola Electric lead Nifty 500 gainers; HEG, Craftsman Automation fall at market open** — Monthly toll revenue data was among the reasons that moved a stock over 5% on the Nifty 500 at market open, while one stock extending its decline toward a fresh 52-week low — here's a look at today's top gainers and losers. — [Source](https://www.cnbctv18.com/market/stocks/irb-infrastructure-ola-electric-nifty-500-gainers-heg-craftsman-automation-sai-life-sciences-share-price-19988093.htm)
- 2026-09-02 — News18: **Market Crash Today: 10 Stocks Defy Selloff, Rally Up To 8% on September 2** — IFCI is among the biggest gainers, surging 8.02% to Rs 94.26, followed by The New India Assurance Company, up 5.67% at Rs 196.3, and Poly Medicure, which gains 5.48% to Rs 1,852.6. — [Source](https://www.news18.com/business/markets/market-crash-today-10-stocks-defy-selloff-rally-up-to-8-on-september-2-ws-l-10305500.html)
- 2026-09-02 — Mint: **Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —2 September 2026** — Breakout stocks to buy or sell: Sumeet Bagadia recommends five breakout stocks to buy today —GHCL Textiles, Gmm Pfaudler, Tarsons Products, Aeroflex Industries, and Sai Life Sciences. — [Source](https://www.livemint.com/market/stock-market-news/breakout-stocks-to-buy-or-sell-sumeet-bagadia-recommends-five-shares-to-buy-today-2-september-2026-11788310076025.html)
- 2026-08-27 — MONEYCONTROL: **Goldman Sachs-backed CRDMO Aragen Life Sciences files IPO papers to raise Rs 800 crore fresh capital** — Aragen Life Sciences IPO size,Aragen Life Sciences IPO DRHP,Aragen Life Sciences IPO news,Aragen Life Sciences IPO details,Goldman Sachs — [Source](https://www.moneycontrol.com/news/business/ipo/goldman-sachs-backed-crdmo-aragen-life-sciences-files-ipo-papers-to-raise-rs-800-crore-fresh-capital-14017035.html)
- 2026-08-26 — Mint: **Buy or sell: Gift Nifty signals gap-up start | Vaishali Parekh recommends three stocks to buy today — 26 August 2026** — Buy or sell indicator: Vaishali Parekh recommends three stocks to buy today — Astral, Sai Life Sciences, and ICICI Bank — [Source](https://www.livemint.com/market/stock-market-news/buy-or-sell-gift-nifty-signals-gap-up-start-vaishali-parekh-recommends-three-stocks-to-buy-today-26-august-2026-11787709370297.html)
- 2026-08-21 — MONEYCONTROL: **Trade Spotlight: How should you trade Sai Life Sciences, EID Parry, Raymond, Glenmark Pharma, MCX India, and others on August 21?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Sai Life Sciences,Shriram Finance,EID Parry (India),Raymond,Glenmark Pharmaceuticals,Multi Commodity Exchange of India, — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-sai-life-sciences-eid-parry-raymond-glenmark-pharma-mcx-india-and-others-on-august-21-14011993.html)
- 2026-07-22 — CNBC-TV18: **Donald Trump to impose 100% tariff on generic pharma imports from 2028, 200% a year later** — Trump's earlier tariffs in this sector pertained to branded and patented drugs, the policy of which has been left unchanged. The earlier policy had left out generic drugs, as nearly 90% of the US prescriptions comprise of them. — [Source](https://www.cnbctv18.com/market/sun-pharma-lupin-cipla-biocon-share-price-donald-trump-generic-drugs-tariffs-timeline-impact-19950953.htm)
- 2026-07-20 — Mint: **Cipla, Ajanta Pharma to Alkem Laboratories: Pharma stocks rise amid weak trends on Dalal Street** — Torrent Pharmaceuticals and Mankind Pharma were the top gainers on the Nifty Pharma index with more than 3% rally each. Cipla, Divi’s Laboratories, Laurus Labs, Alkem Laboratories and Sai Life Sciences shares rose over 2% each. — [Source](https://www.livemint.com/market/stock-market-news/cipla-ajanta-pharma-to-alkem-laboratories-pharma-stocks-rise-amid-weak-trends-on-dalal-street-11784531087488.html)

## Business profile

**Strategic vision:** CRDMO partnering with pharma and biotech for drug development.

### Business segments
- **Discovery Services:** Provides chemistry, biology, DMPK, and toxicology services to aid clients in identifying and optimizing lead drug candidates.
- **Development & Manufacturing:** Supports clinical development and commercial manufacturing through process R&D, analytical method development, and API manufacturing in cGMP-compliant facilities.

### Competitive strengths
- Integrated CRDMO services across discovery, development, and manufacturing.
- cGMP compliant manufacturing facilities for API production.

## Related stocks

- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.85%
- [Ajanta Pharma Limited (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +0.55%
- [Alkem Laboratories Limited (Healthcare)](https://faxioms.com/stocks/alkem) — +2.06%
- [Biocon Limited (Healthcare)](https://faxioms.com/stocks/biocon) — +0.86%
- [Gland Pharma Limited (Healthcare)](https://faxioms.com/stocks/gland) — +0.78%

## Freshness and sources

- Data as of: 2026-11-06
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/sailife
Markdown representation: https://faxioms.com/stocks/sailife?render=md